Life Cycle Management Strategies - Optimizing revenues and defending generic competition
Summary
GBI Researchs latest report, Life Cycle Management Strategies - Optimizing revenues and defending generic competition discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on.
Companies mentioned in the report are AbbVie, Actavis, AstraZeneca, Cipla, Gilead, GlaxoSmithKline, Gleevec, Janssen, MannKind, Merck, Novartis, Orexo, Otsuka, Pfizer, Roche, Salix Pharmaceuticals, Sanofi-Aventis, Solvay, Teva and Vifor Pharma.
Scope
- Introduction of LCM and product life cycle
- Objectives of LCM and factors impacting the choice of strategies
- LCM strategies depending on the way of approach
- Impact of LCM strategies on sales and growth trend of selected products
- Patent term extension and market exclusivity in the US and Europe
- LCM strategies of pipeline drugs of key players
- Keys to successful implementation of LCM strategies
Key Reasons to Purchase
- Identify the key LCM strategies used by most of the pharmaceutical companies
- Analyze the strategies to increase lifecycle and revenues of a drug
- Gain an understanding on the implementation of multiple strategies for a single product by including case studies
- Understand the operational pipeline strategies of key players
Executive Summary
Introduction
Overview of Product Life Cycle
Product Life Cycle Curve
Objectives of Life Cycle Management (LCM)
Classification and Benefits of LCM Strategies
Strategic Planning for LCM
Factors Impacting Choice of LCM Strategies
Developmental Strategies
Indication Expansion/Sequencing and Repositioning
Patient Subpopulations and Personalized Medicine
Reformulation
New Dosage Forms
New Route of Administration
Special Cases
New Dosage Strengths and Regimen
Fixed-Dose Combination and Co-packaging
Next Generation Products and Modified Chemistry
Metabolites
Chiral Switching
Polymorphs
Multiple Developmental Strategy Approach
Commercial Strategies
Rx-to-OTC/BTC Switch
Geographical Expansion
Pricing Strategy and Tactics
Pricing Strategy for Targeting Multiple Indications
Coupons
Co-pay Cards
Awareness, Brand Loyalty and Service Programs
Regulatory and Legal Strategies
Authorized Generics
Legal Defense and Pay for Delay
Citizen’s Petition
Patent Term Extension and Market Exclusivity
The Pharmaceutical Pipeline and LCM
Successful Implementation of LCM Strategies
Appendix
